Sleep Medicine
Volume 7, Issue 4 , Pages 333-339 , June 2006

Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome

  • Jens Carsten Möller

      Affiliations

    • Department of Neurology, Philipps-University, 35033 Marburg, Germany
    • Corresponding Author InformationCorresponding author. Address: Klinik für Neurologie, Philipps-Universität, Rudolf-Bultmann-Str. 8, 35039 Marburg, Germany. Tel.: +49 6421 28 65372; fax: +49 6421 28 67055.
    • ,
  • Yvonne Körner

      Affiliations

    • Department of Psychology, Center for Traffic Sciences, Julius-Maximilians University, 97070 Würzburg, Germany
    • ,
  • Werner Cassel

      Affiliations

    • Department of Internal Medicine, Philipps-University, 35033 Marburg, Germany
    • ,
  • Charlotte Meindorfner

      Affiliations

    • Department of Psychology, Center for Traffic Sciences, Julius-Maximilians University, 97070 Würzburg, Germany
    • ,
  • Hans-Peter Krüger

      Affiliations

    • Department of Psychology, Center for Traffic Sciences, Julius-Maximilians University, 97070 Würzburg, Germany
    • ,
  • Wolfgang H. Oertel

      Affiliations

    • Department of Neurology, Philipps-University, 35033 Marburg, Germany
    • ,
  • Karin Stiasny-Kolster

      Affiliations

    • Department of Neurology, Philipps-University, 35033 Marburg, Germany

Received 29 March 2005 ,Revised 29 July 2005 ,Accepted 7 August 2005.

References 

  1. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12(1):61–65
  2. Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology. 2002;58(3):341–346
  3. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52(9):1908–1910
  4. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian movement disorders group. J Am Med Assoc. 2002;287(4):455–463
  5. Körner Y, Meindorfner C, Möller JC, et al. Predictors of sudden onset of sleep. Mov Disord. 2004;19:1298–1305
  6. Roth T, Rye DB, Borchert LD, et al. Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med. 2003;4(4):275–280
  7. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–545
  8. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4(2):101–119
  9. Walters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord. 1995;10(5):634–642
  10. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4:121–132
  11. Dement W, Rechtschaffen A, Gulevich G. The nature of the narcoleptic sleep attack. Neurology. 1966;16:18–33
  12. Tan EK, Lum SY, Fook-Chong SM, et al. Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls. Neurology. 2002;58(3):465–468
  13. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001;57(8):1392–1396
  14. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wüllner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord. 2003;18(6):659–667
  15. Stiasny K, Möller JC, Oertel WH. Safety of pramipexole in patients with restless legs syndrome. Neurology. 2000;55(10):1589–1590
  16. Hening WA, Allen RP, Earley CJ, Picchietti DL, Silber MH. RLS Task Force of the Standards of Practice Committee of the American Academy of sleep medicine. Sleep. 2004;27:560–583
  17. Gillin JC, Post RM, Wyatt RJ, Goodwin FK, Snyder F, Bunney WE. REM inhibitory effect of l-DOPA infusion during human sleep. Electroencephalogr Clin Neurophysiol. 1973;35(2):181–186
  18. McCann UD, Thorne D, Hall M, et al. The effects of l-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety. Neuropsychopharmacology. 1995;13:41–52
  19. Rihet P, Possamai CA, Micallef-Roll J, Blin O, Hasbroucq T. Dopamine and human information processing: a reaction-time analysis of the effect of levodopa in healthy subjects. Psychopharmacology. 2002;163:62–67
  20. Andreu N, Chale JJ, Senard JM, Thalamas C, Montastruc JL, Rascol O. l-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol. 1999;22:15–23
  21. Ferreira JJ, Galitzky M, Thalamas C, et al. Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Neurology. 2002;58:460–462
  22. Sabbe B, Hulstijn W, Maes M, Pier M, Scharpe S, Zitman F. Psychomotor, neuroendocrine and behavioural effects after oral administration of levodopa in normal volunteers. Psychiatry Res. 2004;128:103–106
  23. Stiasny-Kolster K, Benes H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology. 2004;63:2272–2279
  24. Stiasny-Kolster K, Oertel WH. Low-dose pramipexole in the management of restless legs syndrome. Neuropsychobiology. 2004;50:65–70
  25. Trenkwalder C, Hundemer H-P, Lledo A, et al. Efficacy of pergolide in treatment of restless legs syndrome. Neurology. 2004;62:1391–1397
  26. Wetter TC, Stiasny K, Winkelmann J, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology. 1999;52(5):944–950
  27. Chaudhuri KR. The basis for day and night-time control of symptoms of Parkinson's disease. Eur J Neurol. 2002;3(Suppl. 3):40–43
  28. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol. 1988;11(6):512–519
  29. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197–211
  30. Möller JC, Körner Y, Dodel RC, et al. Pharmacotherapy of Parkinson's disease in Germany. J Neurol, in press.
  31. Bundesamt für Straßenwesen. Begutachtungs-Leitlinien zur Kraftfahrereignung. Bergisch Gladbach: Wirtschaftsverlag NW; 2000;
  32. EMEA. CPMP position statement dopaminergic substances and sudden sleep onset; 2002 (CPMP/578/02).

PII: S1389-9457(05)00191-7

doi: 10.1016/j.sleep.2005.08.009

Sleep Medicine
Volume 7, Issue 4 , Pages 333-339 , June 2006

Article Tools

* Image Usage & Resolution